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Abstract
Introduction: Interleukin (IL)-21 is a member of type I cytokine family. Recent studies indicate that IL-21 can
promote T follicular helper (Tfh) cell differentiation and survival, a specialized T cell subset which provides help for
B cell. It can also regulate the activation, proliferation and differentiation of human B cell and immunoglobulin (Ig)
production as well as isotype switching of plasma cell. Rheumatoid arthritis (RA) is characterized by auto-antibodies
overproduction such as rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibody, suggesting
a pivotal role of Tfh cell and B cell in the pathogenesis of RA. This study aimed to investigate whether IL-21 had a
regulatory effect on Tfh cell and B cell in RA.
Methods: Serum IL-21 concentrations were measured by ELISA. The correlations between serum IL-21 levels and
clinical features of RA patients were analyzed by Spearman’s rank test. The percentages of Tfh-like cells, IL-21
receptor (R) expression on Tfh-like cells and B cells in peripheral blood (PB) were analyzed by flow cytometry.
Peripheral blood mononuclear cells (PBMC) were stimulated by rIL-21 (100 ng/ml) in the presence or absence of
anti-CD40 and/or anti-IgM, and changes of IL-21R, activation-associated surface markers (CD25, CD69 and CD40),
the proliferation, apoptosis and differentiation of B cells were analyzed by flow cytometry. Production of IgG and
IgM in the culture supernatants was determined by ELISA.
Results: The results showed that the serum IL-21 levels in RA patients were significantly higher than that of
healthy controls (HC). IL-21 concentrations were positively correlated with 28-joint count disease activity score
(DAS28) and anti-CCP antibody in RA patients with high IL-21 levels. Furthermore, the frequencies of peripheral
CXCR5+PD-1+CD4+ Tfh-like cells markedly increased in RA patients and the percentages of Tfh-like cells were
positively correlated with DAS28 and anti-CCP antibody levels. Moreover, elevated IL-21 levels were also correlated
with the frequencies of Tfh-like cells. IL-21R expression on both Tfh-like cells and B cells were significantly
enhanced in RA patients. In cultures vitro, exogenous IL-21 upregulated IL-21R expression and activation-associated
surface markers on B cells and promoted more B cell proliferation in RA than in HC. This IL-21-mediated effect
could be reversed by IL-21R-specific neutralizing antibody. Importantly, IL-21 promoted more differentiation of B
cell into plasmablast and higher levels of IgG and IgM production in RA than in HC.
Conclusions: Increased serum IL-21 levels in RA patients correlate with DAS28, anti-CCP antibody and frequencies of
Tfh-like cells. IL-21 supports B cell activation, proliferation and antibody secretion via IL-21R pathway. Thus, IL-21 may
be involved in the pathogenesis of RA and antagonizing IL-21 could be a novel strategy for the therapy of RA.
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Introduction
Interleukin (IL)-21 is a member of the type I cytokine
family and can be secreted by CD4+ T cells including T
follicular helper (Tfh) cells, Th17 cells and natural killer
(NK) T cells [1]. IL-21 signals through the common cyto-
kine receptor g chain in combination with its functional
receptor, IL-21 receptor (R) which is mainly expressed
on B cells and also on T cells, NK cells, dendritic cells,
epithelial cells and fibroblasts [2-4].
It has been reported that IL-21 is able to enhance the
proliferation and effector characteristics of activated
CD4+ and CD8+ T cells [5] and limit the differentiation
of inducible regulatory T cells [6-8]. IL-21 can also mod-
ulate Tfh cell differentiation via the upregulation of
Bcl-6, the transcription factor of Tfh cells [9]. The Tfh
cell is a specialized T cell subset, which is characterized
by increased expression of molecules, including CXCR5,
PD-1, ICOS, CD40L and IL-21 and decreased expression
of CCR7 [10]. Expressing these molecules allows Tfh cell
migration into the germinal center (GC) to provide help
for B cell growth, differentiation and class switching
[11-13]. Reportedly, exposure of CD4+ T cells to IL-21
drives them to differentiate into a Tfh cell subset partly
through modulation of the expression of CXCR5 and
CCR7 by IL-21 in an autocrine manner [14,15]. Also, Tfh
cell regulation of B cell proliferation, differentiation and
antibody production is via the secretion of IL-21 [16-18].
Moreover, IL-21 can directly act on B cells. IL-21 co-
stimulation is capable of promoting plasma cells differ-
entiation from CD27+ memory B cells, inducing class
switch recombination and stimulating poorly responsive
naive cord blood B cells into IgG-secreting plasma cells
in humans [11]. In addition, antigen-specific memory B
cells and plasma cells fail to expand and IgG production
is significantly impaired following secondary immuniza-
tion of IL-21R.KO mice [19]. Furthermore, IL-21 acts in
a B cell-intrinsic fashion to control GC formation [9].
The absence of IL-21 signaling profoundly affects GC
persistence and function, influencing its proliferation,
transition into memory B cells, and affinity maturation
[20]. Thus, the effect of IL-21 on B cells may contribute
to the development of autoimmune diseases.
Rheumatoid arthritis (RA) is characterized by persistent
synovitis and systemic inflammation, frequently leading
to cartilage and bone destruction. Although the etiology
and pathology remain elusive, auto-antibodies to citrulli-
nated cyclic peptides (CCP) and rheumatoid factor (RF)
have been indicated to be associated with the disease
course [21-25]. When transferring auto-antibodies to
mice with certain genetic backgrounds, they may provoke
articular inflammation [26,27]. Importantly, B cells are
the primary source of RF and anti-CCP auto-antibodies
and Tfh cells assist B cells, suggesting a critical role of
Tfh and B cells in the pathogenesis of RA. Recent studies
observe that IL-21R transcript is expressed by synovial
macrophages and fibroblasts from RA patients but not
from patients with osteoarthritis (OA) [28] and IL-21R
deficiency in the K/BxN mouse model of inflammatory
arthritis is sufficient to protect it from arthritis [29].
However, the effect of IL-21 regulation on Tfh and B
cells in the pathogenesis of RA remains largely unknown.
In this report, we investigated the function of IL-21 on
Tfh-like cells and B cells in RA. Our data showed that
increased serum IL-21 levels in RA patients correlated
positively with 28-joint count disease activity score
(DAS28), serum anti-CCP antibodies and frequencies of
Tfh-like cells. IL-21 supported B cell activation, prolifera-
tion and antibody secretion. Strikingly, blockade of IL-




Serum samples were collected from active RA patients
(n = 120) admitted to the ward of The Affiliated Drum
Tower Hospital of Nanjing Medical University, from
July 2010 to September 2012. All patients fulfilled the
American College of Rheumatology criteria for the classi-
fication of RA and they had no other autoimmune or
systemic diseases. None of these patients was pregnant or
menopausal at the time of the study. Age- and sex-
matched healthy controls (HC, n = 80) were obtained
from the medical examination center. Serum samples
were stored at -80°C until used. The study protocol was
approved by the ethics committee of The Affiliated
Drum Tower Hospital of Nanjing Medical University.
Written informed consents were obtained from all
patients and controls. Detailed clinical characteristics and
laboratory features are shown in Table 1.
Enzyme-linked immunosorbent assay (ELISA) for serum IL-
21 levels
Serum IL-21 levels in RA patients and HC were mea-
sured by human IL-21 ELISA kits (Biolegend, San Diego,
CA, USA) according to the instructions of the manufac-
turer. The plate was read at 450 nm and sensitivity of the
ELISA kits used in the experiment was 16 pg/ml.
Clinical data and inflammation index analysis
All patients were followed up to obtain clinical data on
age, sex, disease duration, number of swollen and tender
joints, erythrocyte sedimentation rate (ESR), C-reactive
protein (CRP), anti-CCP antibodies, RF-IgM, RF-IgG and
RF-IgA.
>ESR was evaluated by the Westergren method. Values
≤ 15 mm/h for men and 20 mm/h for women were
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considered normal. CRP was examined by the immunone-
phelometry method and a value > 8 mg/l was considered
positive. Anti-CCP antibody, RF-IgM, RF-IgG and RF-IgA
were tested by ELISA, with normal ranges of 0 to 5 RU/ml
for RF-IgM, and 0 to 20 RU/ml for RF-IgG and RF-IgA.
The DAS28 was calculated as previously described [30].
Detection of IL-21R and activation marker expression by
flow cytometry
Peripheral blood mononuclear cells (PBMC) were isolated
from active RA patients or HC using Ficoll density-gradi-
ent centrifugation. The cell suspension was washed three
times in phosphate- buffered saline (PBS) and then labeled
with the following monoclonal antibodies: phycoerythrin
(PE)-conjugated anti-IL21R (R&D Systems, Minneapolis,
MN, USA), fluorescein isothiocyanate (FITC)- or allophy-
cocyanin (APC)-conjugated anti-CD19, Pecy7-conjugated
anti-CD40, PE-conjugated anti-CD25, FITC-conjugated
anti-CD69, FITC-conjugated anti-CD4, APC-conjugated
anti-CXCR5 and PerCP-Cy5.5-conjugated anti-PD-1 (BD
Biosciences, Franklin Lakes, NJ, USA). For surface marker
staining, cells were maintained in the dark at 4°C for
30 minutes and then washed twice in PBS. IL-21R on Tfh-
like cells and B cells and activation surface markers
expression of B cells were analyzed by flow cytometry.
B cell stimulation by IL-21
PBMC from RA patients or HC were cultured in RPMI
1640 supplemented with 10% fetal calf serum (FCS) and
antibiotics (penicillin 100 IU/ml, streptomycin 100 μg/ml;
Invitrogen, Camarillo, CA, USA) in a humidified atmo-
sphere of 5% CO2 at 37°C. For the studies of IL-21R and
B cell activation, PBMC (1*106/well) were added to
96-well plates directly with or without 100 ng/ml recombi-
nant human IL-21 (Abcam, Cambridge, MA, USA). For
proliferation studies, PBMC (1*106/well) were treated with
3 μg/ml anti-CD40 antibody (eBioscience, San Diego, CA,
USA), 50 ng/ml rIL-4 (PeproTech Inc, Rocky Hill, NJ,
USA) and 100 ng/ml rIL-21 (Abcam). For apoptosis stu-
dies, PBMC (1*106/well) were stimulated with 3 μg/ml
anti-CD40 antibody (eBioscience), and 100 ng/ml rIL-21
(Abcam). For differentiation to plasmablast studies, PBMC
(1*106/well) were treated with 3 μg/ml anti-CD40 antibody
(eBioscience), 5 μg/ml F(ab)2 goat anti-human IgM
(Jackson ImmunoResearch, West Grove, PA, USA) and
100 ng/ml rIL-21 (Abcam). To investigate the possible
mechanism of IL-21, 10 ug/ml anti-IL-21R antibody
(Biolegend) was included in cell cultures.
Quantification of cytokines in serum
Serum cytokines were analyzed using Quantibody
Human TH17 Array 1 (QAH-TH17-1, RayBiotech, Nor-
cross, GA, USA), according to the manufacturer’s specifi-
cation. Each sample was prepared in triplicate. An Axon
scanner 4000B with GenePix software was used to collect
fluorescence intensities.
Proliferation and apoptosis assays
PBMC from RA patients and HC were labeled with 5 μM
carboxyfluorescein diacetate succinimidyl ester (CFSE)
(Invitrogen) in PBS for 10 minutes at 37°C. An excess of
ice-cold RPMI 1640 with 10% FCS was added to the cells
to quench the reaction and cells were washed extensively.
CFSE-labeled cells (1*106/well) were cultured according
to above-mentioned methods. Following 4 days of cul-
ture, cells were collected and then stained with APC-con-
jugated anti-CD19 (BD Biosciences). B cell proliferation
was determined by flow cytometry analysis of CFSE
fluorescence intensity. To detect apoptotic cells, cultured
PBMC were collected and resuspended in 100 μl of 1 ×
binding buffer (10 mM HEPES (pH 7.4), 140 mM NaCl
and 2.5 mM CaCl2) and stained with 5 μl of FITC-conju-
gated Annexin V (BD PharMingen, San Diego, CA, USA)
for 15 minutes at room temperature in the dark and then
analyzed by flow cytometry.
Determination of immunoglobin (Ig) levels
After 4 days’ culture, secreted IgG and IgM in the culture
supernatants were quantitated by ELISA (MABTECH,
Nacka Strand, Sweden) according to the instructions of
the manufacturer. PE-conjugated anti-CD138 (BD Bios-
ciences) expression was analyzed in cultured cells using
flow cytometry.
Table 1 Clinical and laboratory features in 120 patients
with rheumatoid arthritis (RA)
Characteristics Values
Age, yrs 58.95 ± 1.12
Men/women 33/87
Disease duration, yrs 18.02 ± 8.98
DAS28 4.89 ± 0.09
ESR, mm/h 60.86 ± 2.60










Clinical characteristics are presented as mean ± SEM or number (%). DAS28,
28-joint count disease activity score; ESR, erythrocyte sedimentation rate; CRP,
C-reactive protein; RF, rheumatoid factor; Anti-CCP, anti-cyclic citrullinated
peptide antibody; CS, corticosteroid; DMARDs, disease-modifying
antirheumatic drugs; Others, non-steroidal anti-inflammatory drugs, traditional
Chinese medicine or never taking any medication.
Liu et al. Arthritis Research & Therapy 2012, 14:R255
http://arthritis-research.com/content/14/6/R255
Page 3 of 12
Statistical analysis
Data were summarized as means ± standard error of the
mean (SEM). Statistical significance was performed by Stu-
dent’s t-test and the correlation coefficient between serum
IL-21 levels and clinical features in RA patients were ana-
lyzed by Spearman’s rank test. All statistical analyses were
performed using GraphPad Prism software (Graph-Pad,
San Diego, CA, USA). A P-value < 0.05 was considered
significantly different.
Results
Positive correlation of increased IL-21 with disease
activity and auto-antibody production in RA patients
We measured the serum IL-21 levels in RA patients (n =
120) and age-matched HC (n = 80) by ELISA and revealed
that RA patients had significantly higher IL-21 levels than
HC subjects (197.60 ± 32.57 vs. 59.10 ± 3.45 pg/ml, P <
0.01; Figure 1a).
Then the correlations of IL-21 concentrations with clini-
cal activity and auto-antibody levels were analyzed in the
high IL-21 group. IL-21 concentrations > 120.74 pg/ml
(mean + 2SD of the HC group) were defined as high IL-
21. We found that RA patients with elevated IL-21 levels
had a higher DAS28 (r = 0.44, P = 0.006; Figure 1b). In
addition, high IL-21 levels were positively correlated with
anti-CCP antibody levels (r = 0.36, P = 0.02; Figure 1c),
but not with the levels of RF-IgM (r = 0.24, P = 0.11), RF-
IgG (r = 0.31, P = 0.06) and RF-IgA (r = 0.17, P = 0.29;
Figure 1d).
As IL-21 was related to disease activity, we assessed
whether drug treatment had any influence on the concen-
trations of IL-21. RA patients were divided into four
groups: 1) patients taking disease modifying anti-rheumatic
drugs (DMARDs) including a single DMARD and combi-
nation DMARDs; 2) patients taking corticosteroid (CS)
including a single CS and CS plus non-DMARDs; 3)
patients taking CS plus DMARDs, and 4) patients taking
other treatments, including non-steroidal anti-inflammatory
drugs (NSAIDs), traditional Chinese medicine, and patients
never taking any medication. As expected, IL-21 levels were
lowest in patients treated with CS plus DMARDs (133.50 ±
18.22 pg/ml; Figure 1e) and the highest levels of IL-21 were
observed in group 4) who were not receiving CS or
DMARDs (270.60 ± 71.93 pg/ml; Figure 1e), although this
was not statistically significant.
Positive correlation of increased Tfh-like cells with disease
activity and auto-antibody production in RA patients
Recent studies found that Tfh cells could provide help for
B cells and allow formation of long-lived antibody
responses [10,17,31]. First, the frequencies of circulating
CXCR5+PD-1+CD4+ Tfh-like cells were examined. As
shown in Figure 2a, the frequencies of circulating Tfh-like
cells were significantly upregulated in peripheral blood
(PB) of RA patients (5.71% ± 0.53% vs. 2.32% ± 0.13%, P <
0.01; Figure 2a). Serum IL-21 levels in these subjects are
shown in Additional file 1a. Furthermore, the correlations
of high proportions of Tfh-like cells in RA patients, with
clinical activity and auto-antibody production were ana-
lyzed. The frequencies of Tfh-like cells > 4.12% (mean +
2SD of the HC group) were defined as high proportions of
Tfh-like cells. We found that patients with upregulated
frequencies of Tfh-like cells had a higher DAS28 (r = 0.39,
P = 0.02; Figure 2b). In addition, the percentages of Tfh-
like cells were positively correlated with anti-CCP antibo-
dies (r = 0.36, P = 0.04; Figure 2c), but not with RF-IgM
(r = 0.10, P = 0.58), RF-IgG (r = 0.33, P = 0.06) and RF-
IgA (r = 0.12, P = 0.51; Figure 2d) among the RA patients
with high frequency of Tfh-like cells.
Positive correlation of increased IL-21 with the
frequencies of Tfh-like cells in RA patients
Because the source of IL-21 was Tfh cells, Th17 cells and
NK T cells, we next investigated the correlation between
IL-21 levels and the percentages of Tfh-like cells in the
group of RA patients with high IL-21. We found that
IL-21 levels positively correlated with the percentages of
Tfh-like cells (r = 0.49, P = 0.04; Figure 3a). Flow cytome-
try analyses showed that IL-21 was derived from both
CXCR5+CD4+ T cells and CXCR5-CD4+ T cells (1.17% ±
0.27% vs. 1.07% ± 0.25%, P > 0.05; Figure 3b).
To investigate a direct function of IL-21 on Tfh-like cells
in RA, we examined IL-21R expression on Tfh-like cells.
IL-21R expression on Tfh-like cells in RA patients was
substantially augmented compared to HC (6.64% ± 0.97%
vs. 3.03% ± 0.40%, P < 0.05; Figure 3c), but this phenom-
enon was not detected on CXCR5-CD4+T cells (0.62% ±
0.11% vs. 1.00% ± 0.19%, P > 0.05; Figure 3d). Serum IL-21
levels of these subjects are shown in Additional file 1b.
Given that IL-21R expression was significantly increased
in PB of RA patients, we observed the functional relevance
of IL-21 to IL-21R expression in RA. However, patients
with elevated IL-21 levels did not have any relationship
with IL-21R expression on Tfh-like cells (r = 0.28, P =
0.29; Figure 3e). We then cultured PBMC with rIL-21 in
vitro and IL-21R expression was determined. Figure 3f
demonstrated that IL-21R expression on Tfh-like cells
remained unchanged both in RA patients (23.05% ± 2.98%
vs. 24.16% ± 3.07%, P > 0.05; Figure 3f) and in HC (17.36%
± 2.19% vs. 18.59% ± 2.23%, P > 0.05; Figure 3f). This is
consistent with in vivo results. Serum IL-21 levels in these
subjects are shown in Additional file 1c.
The effect of IL-21 on B cell activation in RA patients
First, we found that IL-21R expression was significantly
upregulated on B cells in RA patients (54.88% ± 2.64% vs.
38.39% ± 2.35%, P < 0.01; Figure 4a). Serum IL-21 levels of
these subjects are shown in Additional file 2a. Then we
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cultured PBMC with rIL-21 in vitro and IL-21R expression
was determined. Figure 4b showed that IL-21R expression
on B cells was significantly enhanced in response to rIL-21
in RA patients (29.11% ± 4.11% vs.38.13% ± 4.72%, P <
0.05; Figure 4b) but not in HC (19.84% ± 2.68% vs. 21.71%
± 2.95%, P > 0.05). Serum IL-21 levels in these subjects
were shown in Additional file 2b.
Next, we investigated whether IL-21 was able to regulate
B cell activation. We first found that the expressions of B
cell activation markers (CD25: 56.34% ± 2.53% vs. 28.78%
± 2.29%, P < 0.01; CD69: 1.51% ± 0.24% vs. 0.71% ± 0.18%,
P < 0.05; CD40: 87.85% ± 2.53% vs. 77.13% ± 4.12%, P <
0.05; Figure 4c) were significantly upregulated in RA
patients, suggesting B cells are in an activated state in RA.
Serum IL-21 levels in these subjects are shown in
Additional file 2c. Thus, we supposed that B cell activation
was partly due to elevated IL-21 in RA. Then we cultured
PBMC in the presence and absence of rIL-21 and the
expressions of those markers on B cells were examined.
As shown in Figure 4d, inclusion of rIL-21 led to higher
expressions of CD25, CD69 and CD40 in RA patients and
this response was reversed by anti-IL-21R antibodies
(CD25: 43.48% ± 2.63% vs. 61.63% ± 2.63% vs. 57.74% ±
2.89%, P < 0.05; CD69: 1.48% ± 0.26% vs. 2.85% ± 0.43%
vs. 2.30% ± 0.48%, P < 0.05; CD40: 73.14% ± 1.09% vs.
81.77% ± 1.77% vs. 75.22% ± 1.64%, P < 0.05; Figure 4d).
However, rIL-21 only slightly upregulated CD25 expres-
sion on B cells in HC and had no effect on the expression
of CD69 and CD40 (CD25: 26.92% ± 1.82% vs. 34.71% ±
2.50% vs. 29.14% ± 1.76%, P < 0.05; CD69: 0.73% ± 0.23%
Figure 1 Positive correlation of high serum IL-21 levels with disease activity and auto-antibody production in patients with
rheumatoid arthritis (RA). (a) Serum IL-21 levels of RA patients (n = 120) and healthy controls (HC) (n = 80) were measured by ELISA. (b) There was
positive correlation between serum IL-21 and 28-joint count disease activity score (DAS28) in RA patients with high IL-21 (n = 38). (c) There was a
positive correlation between serum IL-21 and levels of anti-cyclic citrullinated peptide (anti-CCP) antibody in RA patients with high IL-21 (n = 38).
(d) Serum IL-21 had no relationship with levels of rheumatoid factor (RF)-IgM, RF-IgG or RF-IgA in RA patients with high IL-21 (n = 38). (e) Serum IL-21
levels in RA patients treated with different drugs. **P < 0.01; *P < 0.05. DMARDS, disease-modifying antirheumatic drugs; CS, corticosteroids.
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vs. 0.80% ± 0.22% vs. 0.79% ± 0.21%, P > 0.05; CD40:
70.37% ± 1.30% vs. 71.83% ± 1.63% vs. 70.16% ± 1.42%,
P > 0.05; Figure 4d). Serum IL-21 levels in these subjects
are shown in Additional file 2d. To further explore why
IL-21 exposure was prone to activating B cells in RA, we
performed microarray analysis of serum from RA patients.
We found that several kinds of inflammatory factors were
increased (Figure 4e), suggesting an inflammatory micro-
environment in RA. Therefore, it indicates that under an
inflammatory microenvironment in RA patients, IL-21 is
sensitive to activation of B cells.
The impact of IL-21 on B cell proliferation and
differentiation in RA patients
As previous reports suggested that IL-21 could co-stimu-
late mature B cells to proliferate in mice [32,33], we studied
whether it could promote B cell proliferation in RA
patients. Figure 5a demonstrates that in the presence of
anti-CD40 and rIL-4, rIL-21 had more effect on B cell pro-
liferation in RA, evidenced by dilution of CFSE. This effect
was reversed by anti-IL-21R antibodies in both RA patients
(41.65% ± 3.00% vs. 52.82% ± 4.03% vs. 46.50% ± 2.72%, P
< 0.05; Figure 5a) and HC (28.87% ± 3.66% vs. 38.12% ±
2.66% vs. 33.13% ± 3.59%, P < 0.05; Figure 5a). Serum IL-
21 levels in these subjects are shown in Additional file 2e.
Unexpectedly, IL-21 failed to influence B cell apoptosis in
RA patients (24.41% ± 4.82% vs. 24.30% ± 4.89%, P > 0.05;
Figure 5b), whereas it was able to enhance B cell apoptosis
in HC (10.21% ± 1.06% vs. 15.37% ± 2.29%, P < 0.05; Figure
5b). These data indicate different effects of IL-21 on B cell
apoptosis in RA patients and HC. Serum IL-21 levels in
these subjects are shown in Additional file 2f.
Figure 2 Positive correlation of increased T follicular helper (Tfh)-like cells with disease activity and auto-antibody production in
patients with rheumatoid arthritis (RA). (a) Frequencies of circulating CXCR5+PD-1+CD4+ Tfh-like cells were significantly higher in peripheral
blood (PB) of RA patients (n = 47) than in healthy controls (HC) (n = 47). (b) There was positive correlation between Tfh-like cells and 28-joint count
disease activity score (DAS28) in RA patients with high levels of Tfh-like cells (n = 31). (c) There was a positive correlation between Tfh-like cells and
levels of anti-cyclic citrullinated peptide (anti-CCP antibody) in RA patients with high levels of Tfh-like cells (n = 31). (d) Tfh-like cells had no relationship
with levels of rheumatoid factor (RF)-IgM, RF-IgG and RF-IgA in RA patients with high levels of Tfh-like cells (n = 31). **P < 0.01; *P < 0.05.
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As large amounts of RF and anti-CCP antibody appeared
in the serum of RA patients, we next observed the effect of
IL-21 on the production of IgG and IgM by B cells in RA
patients and HC. We showed that rIL-21 upregulated the
frequencies of plasmablasts (CD138+CD19low/+) both in
RA patients (7.30% ± 1.01% vs. 9.24% ± 1.08%, P < 0.05;
Figure 5c) and HC (3.26% ± 0.66% vs. 4.12% ± 0.93%, P <
0.05; Figure 5c). However, IL-21-mediated B cell differen-
tiation was stronger in RA patients than in HC. Further-
more, IL-21 induced B cells to produce higher levels of
IgG and IgM in RA patients (IgG: 297.20 ± 24.77 vs.
353.70 ± 29.30 ng/ml, P < 0.05; IgM: 12.43 ± 4.39 vs. 20.47
± 9.73 ng/ml, P > 0.05; Figure 5d) compared to HC (IgG:
221.60 ± 18.19 vs. 258.50 ± 24.51 ng/ml, P < 0.05; IgM:
3.29 ± 0.18 vs. 3.03 ± 0.19 ng/ml, P > 0.05; Figure 5d),
although there were no marked differences in the secre-
tion of IgM. Serum IL-21 levels in these subjects are
shown in Additional file 2g.
Discussion
Previous studies have detected IL-21R at mRNA and
protein levels in synovial tissue samples from RA
patients [28,34], supporting the idea that IL-21/IL-21R
is implicated in the pathogenesis of RA. In the present
Figure 3 Positive correlation of increased serum IL-21 with circulating T follicular helper (Tfh)-like cells in patients with rheumatoid
arthritis (RA). (a) Serum IL-21 positively correlated with the percentages of circulating Tfh-like cells in RA patients with high IL-21 (n = 16). (b) IL-21
derived from both CXCR5+CD4+ T cells and CXCR5-CD4+ T cells in RA patients (n = 20). (c) IL-21R expression on Tfh-like cells in peripheral blood (PB)
from RA patients (n = 47) was substantially upregulated compared to healthy controls (HC) (n = 34). (d) IL-21R expression on CXCR5-CD4+T cells was
unchanged in RA patients. (e) IL-21 had no relationship with IL-21R expression on Tfh-like cells in RA patients with high IL-21 (n = 16). (f) Peripheral
blood mononuclear cells (PBMC) isolated from either RA patients (n = 8) or HC (n = 8) were cultured with 10 μg/ml phytohemagglutinin (PHA; Sigma)
in the presence and absence of rIL-21 (100 ng/ml), and IL-21R expression on Tfh-like cells was analyzed after 48 h.*P < 0.05; n.s., not significant. PBS,
phosphate-buffered saline.
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study we showed serum IL-21 levels were significantly
increased in RA patients. IL-21 concentrations were
positively correlated with anti-CCP antibodies in the
high IL-21 group of RA patients, suggesting IL-21 might
be involved in auto-antibody production. Moreover, the
high IL-21 levels were correlated with DAS28, indicating
that IL-21 relates to clinical activity, which is consistent
with the study by Rasmussen et al.[35].
Tfh cells are a subset of T cells that specialize in provid-
ing help for B cells. They are characterized by increased
expression of molecules including CXCR5, PD-1, ICOS,
CD40L and IL-21, and decreased expression of CCR7 [10].
Figure 4 The effect of IL-21 on IL-21 receptor (R) of B cells and B cell activation in patients with rheumatoid arthritis (RA). (a) IL-21R
expression on B cells was substantially upregulated in RA patients (n = 45) compared to healthy controls (HC) (n = 38). (b) Peripheral blood
mononuclear cells (PBMC) from either RA patients (n = 14) or HC (n = 11) were cultured with or without rIL-21 (100 ng/ml), and IL-21R expression
on B cells was analyzed after 48 h. (c) Activation marker expressions on B cells were significantly upregulated in RA patients (n = 20) compared to
HC (n = 15). (d) PBMC isolated from RA patients (n = 10) and HC (n = 10) were stimulated with rIL-21 (100 ng/ml) or rIL-21 in combination with
anti-IL-21R antibody (10 ug/ml), and activation marker expressions on B cells were examined after 72 h. (e) Microarray analysis of cytokines in serum
from RA patients (n = 6) and HC (n = 4). **P < 0.01; *P < 0.05; n.s., not significant. PBS, phosphate-buffered saline.
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Most of the Tfh cells are located in the light zone of GC in
secondary lymphoid tissue in human, but it was reported
that human blood CD4+CXCR5+ T cells also shared func-
tional properties with Tfh cells [17]. In our study we
observed that the frequencies of circulating Tfh-like cells
markedly increased in PB from RA patients, suggesting
Tfh-like cells might be involved in the pathogenesis of RA.
As the function of Tfh cells was assisting B cells to secret
antibodies, we next assessed the relationship between Tfh-
like cells and anti-CCP antibodies/RF. The results revealed
that the high percentages of Tfh-like cells were positively
correlated with anti-CCP antibodies but not RF.
Based on the relationship between IL-21 and auto-
antibody production, we focused on the role of IL-21 in
regulating Tfh-like cells and B cells, two principal cells
contributing to antibody secretion. First of all, we found
that high IL-21 levels were positively correlated with the
frequencies of Tfh-like cells. Furthermore, IL-21R expres-
sion on Tfh-like cells was upregulated, confirming that
Tfh-like cells are potent responders for IL-21. Reportedly,
IL-21 was essential for B cell activation [36] and was the
most potent T cell-derived cytokine to induce B cell prolif-
eration from PB, spleen, and tonsil in humans [11]. Our
study demonstrated that IL-21 was able to directly pro-
mote B cell activation in vitro in RA patients. Moreover,
IL-21 induced B cell expansion more significantly in RA
patients than in HC. A balance between the proliferation
and apoptosis of immune cells is needed to maintain
homeostasis of the immune system. In this study, IL-21
had different impacts on the apoptosis of B cells in RA
patients and HC. In HC, IL-21 promoted B cell apoptosis.
A previous study demonstrated that IL-21 stimulation of
murine B cells led to a rapid decrease of anti-apoptotic
protein Bcl-2 and Bcl-XL at mRNA and protein levels [37],
which might be a possible mechanism of our result. How-
ever, we did not find the influence of IL-21 on B cell apop-
tosis in RA patients. Notably, our results have shown that
IL-21 stimulation promoted B cell activation and expan-
sion in RA. This discrepancy implicates that IL-21 might
be prone to inducing B cell activation and expansion
instead of apoptosis in RA.
Ig production is a key component in B cell differentiation
and the generation of protective humoral immune
responses. Accumulated evidence suggests that IL-21 in
combination with CD40L and/or anti-IgM is an inducer of
plasma cell differentiation [11,38]. Moreover, IL-21 has also
been shown to be a critical cytokine that stimulates IgG
production compared to IL-2, IL-4 and IL-10 [11,38]. We
found that IL-21 induced anti-CD40 and anti-IgM-stimu-
lated B cells to differentiate into plasmablasts, and yielded
Figure 5 Impact of IL-21 on B cell proliferation and differentiation in patients with rheumatoid arthritis (RA). (a) Peripheral blood
mononuclear cells (PBMC) isolated from RA patients (n = 6) and healthy controls (HC) (n = 6) were labeled with carboxyfluorescein diacetate
succinimidyl ester (CFSE) and then stimulated with anti-CD40 (3 μg/ml) and rIL-4 (50 ng/ml) in the presence or absence of rIL-21 (100 ng/ml).
After 96 h of culture, B cell proliferation was determined. (b) PBMC isolated from RA patients (n = 14) and HC (n = 8) stimulated with anti-CD40
(3 μg/ml) in the presence or absence of rIL-21 (100 ng/ml). Cells stained with Annexin V were examined after 72 h. (c) PBMC isolated from RA
patients (n = 20) and HC (n = 15) were stimulated with a combination of anti-CD40 (3 μg/ml) and anti-IgM (5 μg/ml) in the presence or
absence of rIL-21 (100 ng/ml). After 96 h, the frequencies of CD138+CD19low/+ plasmablasts were determined. (d) Secretion of IgG and IgM in
culture supernatant was assessed by ELISA *P < 0.05; n.s., not significant. PBS, phosphate-buffered saline.
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higher levels of IgG and IgM in RA patients compared to
HC, although there were no significant differences in the
secretion of IgM. It indicates that the responsibility of IL-
21 for Ig production may be stronger in RA patients.
Through microarray analysis we found many inflammatory
factors levels were upregulated in serum from RA patients,
suggesting an inflammatory microenvironment in RA.
Among these elevated cytokines, IL-2, IL-4, IL-6, IL-7 and
IL-10 are all critical for B cell survival and differentiation
[39-43]. We speculate that these cytokines might also play
important roles in regulating B cell function in RA, and
under this inflammatory microenvironment, IL-21 is prone
to inducing B cell activation, expansion and differentiation.
IL-21 has been implicated in autoimmunity disease via
the IL-21R pathway. Jang et al. addressed the theory that
IL-21R deficiency in the K/BxN mouse model of inflam-
matory arthritis was sufficient to protect it from arthritis
[29]. Blocking the IL-21 pathway with IL-21R-Fc fusion
protein has been shown to ameliorate the clinical and his-
tologic signs of arthritis and dramatically reduce total
IgG1 and inflammatory cytokines levels [44]. Similarly,
IL-21R-deficient BXSB.B6-Yaa+/J mice presented none of
the abnormal characteristics of systemic lupus erythema-
tosus (SLE) in IL-21R-competent Yaa mice, including
hypergammaglobulinemia, auto-antibody production
and reduced frequencies of marginal zone B cells [45].
Blockade of IL-21 with IL-21R-Fc fusion protein has
resulted in fewer IgG glomerular deposits, circulating
dsDNA auto-antibodies, total sera IgG1, IgG2a and lym-
phadenopathy in the lupus-prone MRL-Faslpr mouse [46].
Corresponding to therapeutic efficacy, administration
of IL-21R-Fc fusion protein to BXSB.B6-Yaa+/J mice,
another model of lupus, decreased lymphocyte activation
and circulating IgG1 levels [47]. In our study, IL-21
induced B cell activation and proliferation could be
reversed by anti-IL-21R antibody, which may indicate that
IL-21 regulates B cell function via binding with IL-21R.
Conclusions
Our results highlight that increased serum IL-21 levels in
RA patients correlate with serum DAS28, anti-CCP anti-
body and the frequencies of Tfh-like cells. IL-21 supports
B cell activation, proliferation and antibody secretion via
the IL-21R pathway. All these data indicate IL-21 is
involved in the pathogenesis of RA. Therefore, it opens
avenues for the possibility that IL-21 might be targeted by
therapeutic strategies for the clinical management of RA
in the future.
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